LO-ZUMANDIMINE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LO-ZUMANDIMINE (LO-ZUMANDIMINE).

How it works

LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.

What the body does with it

Metabolism	Primarily metabolized by CYP3A4 and CYP2C8 enzymes. Minor contributions from CYP1A2 and CYP2D6. Undergoes glucuronidation via UGT1A1.
Excretion	Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air.
Half-life	Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 mL/min, half-life extends to 20–28 hours, necessitating dose interval adjustment.
Protein binding	94–97% bound primarily to serum albumin (binding site II), with minor binding to alpha-1-acid glycoprotein. Binding is saturable at high plasma concentrations (>10 mcg/mL), increasing free fraction.
Volume of Distribution	Volume of distribution is 1.2–1.8 L/kg, indicating extensive tissue distribution. The central compartment Vd is 0.4 L/kg; peripheral compartment reflects accumulation in liver, kidneys, and adipose tissue. Clinical meaning: Loading dose may be required for rapid achievement of steady-state concentration.
Bioavailability	Oral bioavailability is 70–80% due to first-pass hepatic metabolism (CYP3A4). Rectal suppository bioavailability is 60–70%. Intramuscular bioavailability is >95%. Sublingual administration yields 85–90% bioavailability (avoiding first-pass effect).
Onset of Action	Oral: Onset occurs within 30–45 minutes following an oral dose (peak plasma concentration at 2 hours). Intravenous: Onset is within 5–10 minutes (immediate effect). Intramuscular: Onset is 15–30 minutes.
Duration of Action	Duration of clinical effect is 8–12 hours after oral administration and 6–8 hours after IV administration. Note: Duration is prolonged in hepatic impairment (up to 18 hours) and in patients taking CYP3A4 inhibitors (e.g., ketoconazole).

Classification & Brands

Dosing & administration

10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.

Dosage form	TABLET
Renal impairment	eGFR ≥30 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 10 mg daily; eGFR <15 mL/min: contraindicated.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg daily; Child-Pugh C: contraindicated.
Pediatric use	Children ≥6 years: 0.2 mg/kg/dose (max 10 mg) orally once daily; may increase to 0.4 mg/kg (max 20 mg) after 2 weeks.
Geriatric use	Initiate at 10 mg orally once daily; maximum 20 mg daily. Monitor renal function and avoid in patients with eGFR <30 mL/min.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LO-ZUMANDIMINE (LO-ZUMANDIMINE).

Breastfeeding	Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infant; manufacturer recommends discontinuing breastfeeding or drug.
Teratogenic Risk	First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Possible fetal growth restriction and oligohydramnios; avoid use unless maternal benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

WARNING: SERIOUS SKIN REACTIONS AND OCULAR TOXICITY. LO-ZUMANDIMINE can cause severe dermatologic adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Permanently discontinue for any life-threatening or severe reactions. Also, retinal vein occlusion (RVO) has been reported; monitor for visual symptoms and perform ophthalmologic evaluation urgently.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to LO-ZUMANDIMINE or any excipients. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Active severe infection.

Clinical Precautions

Precautions

Monitor for skin toxicity; interrupt or discontinue based on severity. Assess for ocular symptoms such as blurred vision, photophobia, or visual field defects. Avoid concurrent use with strong CYP3A4 inhibitors or inducers. May impair fertility. Use effective contraception during treatment and for 4 weeks after last dose. Cautious use in patients with hepatic impairment.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LO-ZUMANDIMINE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LO-ZUMANDIMINE (LO-ZUMANDIMINE).

How it works

What the body does with it

Metabolism	Primarily metabolized by CYP3A4 and CYP2C8 enzymes. Minor contributions from CYP1A2 and CYP2D6. Undergoes glucuronidation via UGT1A1.
Excretion	Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air.
Half-life	Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 mL/min, half-life extends to 20–28 hours, necessitating dose interval adjustment.
Protein binding	94–97% bound primarily to serum albumin (binding site II), with minor binding to alpha-1-acid glycoprotein. Binding is saturable at high plasma concentrations (>10 mcg/mL), increasing free fraction.
Volume of Distribution	Volume of distribution is 1.2–1.8 L/kg, indicating extensive tissue distribution. The central compartment Vd is 0.4 L/kg; peripheral compartment reflects accumulation in liver, kidneys, and adipose tissue. Clinical meaning: Loading dose may be required for rapid achievement of steady-state concentration.
Bioavailability	Oral bioavailability is 70–80% due to first-pass hepatic metabolism (CYP3A4). Rectal suppository bioavailability is 60–70%. Intramuscular bioavailability is >95%. Sublingual administration yields 85–90% bioavailability (avoiding first-pass effect).
Onset of Action	Oral: Onset occurs within 30–45 minutes following an oral dose (peak plasma concentration at 2 hours). Intravenous: Onset is within 5–10 minutes (immediate effect). Intramuscular: Onset is 15–30 minutes.
Duration of Action	Duration of clinical effect is 8–12 hours after oral administration and 6–8 hours after IV administration. Note: Duration is prolonged in hepatic impairment (up to 18 hours) and in patients taking CYP3A4 inhibitors (e.g., ketoconazole).

Classification & Brands

Dosing & administration

10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.

Dosage form	TABLET
Renal impairment	eGFR ≥30 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 10 mg daily; eGFR <15 mL/min: contraindicated.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg daily; Child-Pugh C: contraindicated.
Pediatric use	Children ≥6 years: 0.2 mg/kg/dose (max 10 mg) orally once daily; may increase to 0.4 mg/kg (max 20 mg) after 2 weeks.
Geriatric use	Initiate at 10 mg orally once daily; maximum 20 mg daily. Monitor renal function and avoid in patients with eGFR <30 mL/min.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LO-ZUMANDIMINE (LO-ZUMANDIMINE).

Breastfeeding	Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infant; manufacturer recommends discontinuing breastfeeding or drug.
Teratogenic Risk	First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Possible fetal growth restriction and oligohydramnios; avoid use unless maternal benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to LO-ZUMANDIMINE or any excipients. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Active severe infection.